Zacks Research Estimates Alkermes’ Q3 Earnings (NASDAQ:ALKS)

Alkermes plc (NASDAQ:ALKS) – Equities researchers at Zacks Research cut their Q3 2026 earnings estimates for shares of Alkermes in a research note issued to investors on Wednesday, April 9th. Zacks Research analyst R. Department now anticipates that the company will post earnings of $0.23 per share for the quarter, down from their previous estimate of $0.24. The consensus estimate for Alkermes’ current full-year earnings is $1.31 per share. Zacks Research also issued estimates for Alkermes’ Q1 2027 earnings at $0.18 EPS.

Alkermes (NASDAQ:ALKS) last announced its quarterly earnings data on Wednesday, February 12th. The company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.81 by $0.11. Alkermes had a net margin of 23.57% and a return on equity of 30.80%.

Several other equities research analysts have also commented on the stock. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Alkermes from $40.00 to $52.00 and gave the stock a “buy” rating in a research report on Thursday, March 27th. StockNews.com upgraded Alkermes from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 13th. Royal Bank of Canada started coverage on Alkermes in a report on Thursday, March 13th. They set a “sector perform” rating and a $40.00 target price on the stock. The Goldman Sachs Group raised their price target on Alkermes from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Friday, February 14th. Finally, HC Wainwright restated a “neutral” rating and issued a $46.00 price objective on shares of Alkermes in a research report on Thursday, February 13th. Four analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $38.50.

Alkermes Stock Performance

ALKS opened at $27.00 on Friday. The company has a market cap of $4.45 billion, a price-to-earnings ratio of 12.44, a PEG ratio of 2.20 and a beta of 0.39. Alkermes has a one year low of $22.90 and a one year high of $36.45. The business’s fifty day moving average is $33.14 and its two-hundred day moving average is $30.45.

Institutional Investors Weigh In On Alkermes

A number of institutional investors have recently added to or reduced their stakes in ALKS. Venturi Wealth Management LLC acquired a new position in shares of Alkermes in the 4th quarter valued at about $25,000. EverSource Wealth Advisors LLC raised its holdings in Alkermes by 106.2% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,635 shares of the company’s stock valued at $47,000 after buying an additional 842 shares during the period. Blue Trust Inc. lifted its position in Alkermes by 2,231.5% during the fourth quarter. Blue Trust Inc. now owns 1,702 shares of the company’s stock valued at $49,000 after buying an additional 1,629 shares in the last quarter. Smartleaf Asset Management LLC grew its stake in Alkermes by 558.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 2,950 shares of the company’s stock worth $85,000 after buying an additional 2,502 shares during the period. Finally, GF Fund Management CO. LTD. acquired a new stake in shares of Alkermes in the fourth quarter worth $98,000. Hedge funds and other institutional investors own 95.21% of the company’s stock.

Insider Buying and Selling

In related news, EVP Craig C. Hopkinson sold 144,419 shares of the stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $35.53, for a total value of $5,131,207.07. Following the transaction, the executive vice president now directly owns 57,875 shares of the company’s stock, valued at approximately $2,056,298.75. This trade represents a 71.39 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 4.89% of the company’s stock.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.